Tiffany Carson named co-leader of Health Outcomes and Behavior Program at Moffitt

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Moffitt, 1ST Biotherapeutics collaborate to advance immuno-oncology

Moffitt Cancer Center and 1ST Biotherapeutics are collaborating to accelerating innovative cancer research and clinical development.

February 14, 2025

Vol.51 No.06

Clinical Trials & Tribulations

Chadi Nabhan: Why I wrote a book about cancer

Almost all of us who have practiced oncology for years have encountered situations where we have had to counsel caregivers and guide them throughout their loved ones’ journeys. We have faced patients who took complementary therapies to an extreme; some to a point where they wouldn’t share what they were taking for fear that we might demand they stop.

An elephant in the room: Grief in young adults with cancer

Young adults with cancer are starting to break the silence about grief. Most people think of grief following the death of a loved one, but grief can accompany any event that disrupts or challenges our sense of normalcy or ourselves. During this first week of December, National Grief Awareness Week, we can raise awareness about grief in young adults with cancer to help ensure that no one grieves alone. xxx:more

December 06, 2024

Vol.50 No.45

By Casey Walsh

Clinical Roundup

Only half of young patients with cancer report a discussion on fertility preservation

Only half of people with early-onset cancers reported discussing fertility preservation options prior to their oncology treatments, according to results of a cross-sectional study published in JAMA Network Open.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

November 08, 2024

Vol.50 No.42